It has been announced this week that The Medicines and Healthcare products Regulatory Agency (MHRA) have now authorised this new indication for Anastrozole, a hormone treatment used for breast cancer in post-menopausal women.

Although Anastrozole was already authorised for the use of the treatment of breast cancer in post-menopausal women and has been used off-label for prevention,  this announcement confirms the authorisation for prevention in post-menopausal women at moderate or high risk of developing the disease.

According to Gov.UK, Breast cancer is the most common type of cancer in the UK and statistics say that around 1 in 7 women will be diagnosed with breast cancer in their lifetime.

Evidence for the effectiveness of Anastrozole for the prevention of breast cancer was based on the IBIS-II study, which is an international, randomised double-blind, placebo controlled trial. This showed that fewer women developed breast cancer in the Anastrozole group compared to the placebo group.

To read the full report, click here:

MHRA authorises enzyme inhibitor Anastrozole to prevent breast cancer in post-menopausal women – GOV.UK (www.gov.uk)